Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

• Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-Rad granted subsequent investment option upon FDA clearance IRVINE, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced a partnership agreement with Bio-Rad Laboratories (NYSE:BIO), a global leader in life science research and clinical diagnostics products, for the commercializati ...